The short answer
The MHRA issued a Drug Safety Update on 5 February 2026 warning of a likely association between semaglutide (Wegovy, Ozempic and Rybelsus) and non-arteritic anterior ischaemic optic neuropathy. A European review estimated the frequency at up to 1 in 10,000 people taking it.
Key facts
- Issued
- 5 February 2026
- Regulator
- MHRA (United Kingdom)
- Products
- Wegovy, Ozempic, Rybelsus
- Condition
- Non-arteritic anterior ischaemic optic neuropathy
- Estimated frequency
- Up to 1 in 10,000
- Presentation
- Sudden painless vision loss in one eye
- Action if confirmed
- Discontinue semaglutide
What NAION is
Non-arteritic anterior ischaemic optic neuropathy is damage to the optic nerve head caused by reduced blood supply, not by inflammation of the arteries, which is what the non-arteritic distinction means. It typically presents as sudden, painless loss or blurring of vision in one eye. It is uncommon in the general population and the visual loss is frequently permanent.
What the MHRA said
The Drug Safety Update of 5 February 2026 describes a likely association between semaglutide and NAION across all three UK products: Wegovy, Ozempic and Rybelsus. A European review estimated the frequency at up to 1 in 10,000 people taking semaglutide, which places it in the very rare category. The guidance is that patients presenting with these symptoms should be urgently referred for specialist ophthalmological examination, and that semaglutide should be discontinued if NAION is confirmed.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The detail specific to the UK market
The update makes a point that says a great deal about how these medicines are actually obtained here: semaglutide may not appear on a patient's medical record when it has been privately prescribed, so anyone presenting with these symptoms should be asked directly about semaglutide use. A large private prescription market means the drug history in front of a clinician may be incomplete, and the guidance is written around that reality rather than around an idealised record.
Where the signal came from
The published work behind it includes a 2024 study in JAMA Ophthalmology by Hathaway and colleagues examining NAION risk in patients prescribed semaglutide, followed by further analysis by Cai and colleagues in the same journal in 2025. A regulator issuing a safety update on that basis is the pharmacovigilance system working as designed: a signal detected, investigated, and communicated with a frequency estimate attached.
How to read a 1-in-10,000 estimate
Very rare, and that needs careful reading in both directions. It does not mean the association is unimportant. Permanent vision loss is a serious outcome and the population taking semaglutide is very large, so a rare event across millions of users is not a small number of people. It also does not mean the risk is established as causal; regulators use language such as likely association because the evidence supports action without establishing mechanism.
What this has to do with research material
Nothing directly, and the distinction is worth making. This is a safety communication about licensed medicines prescribed to patients and monitored through a pharmacovigilance system. Material supplied for laboratory research sits outside that system entirely, which is a limitation of research material rather than a reassurance about it. There is no equivalent monitoring, no Yellow Card signal detection, and no regulator issuing updates.
Frequently asked questions
How common is NAION with semaglutide?
A European review estimated up to 1 in 10,000 people taking it, which is the very rare category. The MHRA describes it as a likely association.
What should someone do if they have symptoms?
The MHRA guidance is urgent referral for specialist ophthalmological examination. This is a clinical matter for a prescriber, not something to self-assess.
Why does the MHRA mention private prescriptions?
Because privately prescribed semaglutide may not appear on a patient's medical record, so a clinician may not know it is being taken unless they ask.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- RefMHRA Drug Safety Update. Semaglutide and NAION, 5 February 2026assets.publishing.service.gov.uk
- RefMHRA Safety Roundup: February 2026gov.uk
- PubMedHathaway JT et al., Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol 2024 (PMID 38958939)pubmed.ncbi.nlm.nih.gov
- PubMedCai CX et al., Semaglutide and NAION. JAMA Ophthalmol 2025 (PMID 39976940)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Target Trial Emulation: Making Observational Data BehaveA method for analysing routine health records as though a trial had been designed. Why it exists, what it fixes, and what it cannot fix.
- What the Cardiovascular and Kidney Data Actually IsA 2025 target trial emulation examined GLP-1 outcomes in adults with obesity. What that design can support, and how it differs from a randomised trial.
- Tirzepatide in Heart Failure With Preserved Ejection FractionA target trial emulation in Nature Communications examined tirzepatide in HFpEF. Why this population is studied and what the design supports.
- The Correction Nobody ReadsThe aleniglipron Phase 2b carries a publisher correction. So does the survodutide comparison. Checking for one is a step almost everyone skips.
- Amycretin's Move to Phase 3Novo Nordisk advanced amycretin to Phase 3 in 2026 on the strength of a Lancet phase 1b/2a. What that early trial was, and what it was not.